Kadmon Holdings Inc (NYSE:KDMN) shares traded down 5.5% on Thursday . The company traded as low as $2.32 and last traded at $2.39, 691,400 shares traded hands during mid-day trading. A decline of 22% from the average session volume of 885,221 shares. The stock had previously closed at $2.53.
A number of equities analysts have recently weighed in on the company. ValuEngine upgraded Kadmon from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Tuesday. Finally, Oppenheimer assumed coverage on Kadmon in a report on Wednesday, June 26th. They issued an “outperform” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Kadmon presently has an average rating of “Buy” and an average price target of $7.88.
The business has a fifty day moving average of $2.38 and a 200 day moving average of $2.38. The stock has a market cap of $318.25 million, a price-to-earnings ratio of -2.32 and a beta of 2.09. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.99 and a quick ratio of 2.98.
Kadmon (NYSE:KDMN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Kadmon had a negative return on equity of 96.96% and a negative net margin of 3,974.23%. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.46 million. On average, analysts expect that Kadmon Holdings Inc will post -0.37 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC boosted its position in Kadmon by 20.6% during the first quarter. Vivo Capital LLC now owns 12,606,605 shares of the company’s stock worth $33,281,000 after purchasing an additional 2,152,060 shares during the period. BlackRock Inc. boosted its position in Kadmon by 23.5% during the second quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock worth $17,363,000 after purchasing an additional 1,605,568 shares during the period. Vanguard Group Inc. boosted its position in Kadmon by 5.9% during the second quarter. Vanguard Group Inc. now owns 5,713,561 shares of the company’s stock worth $11,770,000 after purchasing an additional 320,710 shares during the period. Boxer Capital LLC bought a new stake in Kadmon during the second quarter worth approximately $7,597,000. Finally, Sofinnova Investments Inc. boosted its position in Kadmon by 31.8% during the second quarter. Sofinnova Investments Inc. now owns 2,204,202 shares of the company’s stock worth $4,540,000 after purchasing an additional 532,432 shares during the period. Hedge funds and other institutional investors own 75.50% of the company’s stock.
Kadmon Company Profile (NYSE:KDMN)
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: Diversification in Your Portfolio
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.